Adding fast‐acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes: A randomized, 18‐week, open‐label, phase 3 trial (onset 3)

AIM: To confirm glycaemic control superiority of mealtime fast‐acting insulin aspart (faster aspart) in a basal–bolus (BB) regimen vs basal‐only insulin. MATERIALS AND METHODS: In this open‐label, randomized, 18‐week trial (51 sites; 6 countries), adults (n = 236) with inadequately controlled type 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodbard, Helena W., Tripathy, Devjit, Vidrio Velázquez, Maricela, Demissie, Marek, Tamer, Søren C., Piletič, Milivoj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5637905/
https://www.ncbi.nlm.nih.gov/pubmed/28345792
http://dx.doi.org/10.1111/dom.12955

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5637905/
https://www.ncbi.nlm.nih.gov/pubmed/28345792
http://dx.doi.org/10.1111/dom.12955

Ejemplares similares